



Petra H. Wirtz (Autor)

**Smoking, vital exhaustion and glucocorticoid sensitivity of
proinflammatory cytokine release**

Petra H. Wirtz

Smoking, vital exhaustion and
glucocorticoid sensitivity of
proinflammatory cytokine release



Cuvillier Verlag Göttingen

<https://cuvillier.de/de/shop/publications/3421>

Copyright:

Cuvillier Verlag, Inhaberin Annette Jentsch-Cuvillier, Nonnenstieg 8, 37075 Göttingen, Germany
Telefon: +49 (0)551 54724-0, E-Mail: info@cuvillier.de, Website: <https://cuvillier.de>

CONTENTS

1.	Introduction	1
1.1	Cardiovascular disease and inflammation	4
1.1.1	Atherogenesis	4
1.1.1.1	Endothelial dysfunction	5
1.1.1.2	Potential causes of endothelial dysfunction	6
1.1.1.3	Fatty-streaks	7
1.1.1.4	Formation of an advanced, complicated lesion of atherosclerosis	9
1.1.1.5	Unstable fibrous plaques	10
1.1.2	The role of monocytes	12
1.1.3	Angiogenic inflammatory markers	13
1.1.3.1	Tumor necrosis factor (TNF)- α	14
1.1.3.2	Interleukin (IL)-6	15
1.1.3.3	C-reactive protein (CRP)	17
1.1.4	Conclusions for experimental design	18
1.2	Other independent risk factors for cardiovascular disease	19
1.2.1	Smoking – a behavioral risk factor	19
1.2.1.1	Atherogenic effects of smoking	20
1.2.1.1.1	Atherogenic effects of smoking in blood	20
1.2.1.1.2	Atherogenic effects of smoking on serum lipids and lipoproteins	22
1.2.1.1.3	Atherogenic effects of smoking on artery wall and vasculature	23
1.2.1.1.4	Further atherogenic effects	24

CONTENTS

1.2.1.2	Inflammatory markers in smokers	25
1.2.2	Vital exhaustion – a psychological risk factor	26
1.2.2.1	Vital exhaustion and the risk of negative coronary outcomes	27
1.2.2.2	Inflammatory markers, infection and vital exhaustion	27
1.2.2.3	A model of the association of vital exhaustion with acute coronary syndromes	28
1.3	Glucocorticoids and glucocorticoid release in smokers and in vital exhaustion	30
1.3.1	Glucocorticoids	30
1.3.1.1	Hypothalamic-pituitary-adrenal (HPA) axis and cortisol	30
1.3.1.2	Receptor types for glucocorticoids and signal transduction	32
1.3.1.3	Effects of glucocorticoids on immunity and inflammation	35
1.3.1.4	Stress-induced glucocorticoid secretion, blunted HPA axis responses and susceptibility to inflammatory diseases	37
1.3.2	Glucocorticoids and smoking	39
1.3.2.1	Effects of nicotine on the HPA axis	39
1.3.2.2	Glucocorticoid release in smokers	40
1.3.3	Glucocorticoid release in vital exhaustion	41
1.3.4	Conclusions for experimental design	41
1.4	Glucocorticoid sensitivity	42
1.4.1	<i>Ex-vivo</i> assessment of glucocorticoid sensitivity of cytokine release	44

1.4.1.1	Overview	44
1.4.1.2	Glucocorticoid sensitivity assay: Stimulation with LPS and inhibition via coincubated glucocorticoids	45
1.4.1.2.1	Stimulation with LPS	45
1.4.1.2.2	Coincubation with glucocorticoids	46
1.4.1.3	Cytokine measurement via ELISA	48
1.4.1.4	An index for glucocorticoid sensitivity: the IC ₅₀	49
1.4.2	Empirical studies on glucocorticoid sensitivity of immune responses	50
1.4.2.1	Ontogeny of glucocorticoid sensitivity	50
1.4.2.2	Endogenous glucocorticoid release and glucocorticoid sensitivity	51
1.4.2.2.1	Circadian changes in glucocorticoid release and glucocorticoid sensitivity	51
1.4.2.2.2	Psychological stress and glucocorticoid sensitivity ...	52
1.4.2.2.2.1	Animal studies	52
1.4.2.2.2.2	Human studies	53
1.4.2.2.3	Exercise and glucocorticoid sensitivity	55
1.4.2.2.4	Glucocorticoid sensitivity and pathological endo- genous glucocorticoid release: hypocortisolism and hypercortisolism	56
1.4.2.3	Cytokines and glucocorticoid sensitivity	57
1.4.2.4	Glucocorticoid sensitivity and diseases	60
1.4.2.4.1	Glucocorticoid sensitivity and inflammatory diseases	60
1.4.2.4.2	Glucocorticoid sensitivity and exhaustion-related diseases	61
1.4.2.5	Summary	62

CONTENTS

1.4.3	Molecular determinants of glucocorticoid sensitivity	63
1.4.3.1	Glucocorticoid sensitivity determining parameters and influencing factors: an overview	64
1.4.3.2	Specific factors that alter glucocorticoid sensitivity ...	70
1.4.3.2.1	Endogenous glucocorticoid release	70
1.4.3.2.2	Cytokines	71
1.4.4	Conclusions for experimental design	75
1.5	Summary: Conclusions for experimental design....	76
2.	Glucocorticoid sensitivity in smokers	77
2.1	Abstract	77
2.2	Introduction	78
2.3	Materials and Methods	80
2.3.1	Subjects	80
2.3.2	Experimental protocol	81
2.3.3	Glucocorticoid sensitivity and assay	82
2.3.4	Biochemical analyses	83
2.3.5	Statistical analyses	83
2.4	Results	84
2.4.1	Health factors	84
2.4.2	Basal inflammatory measures	86
2.4.3	Stimulation of cytokine production	86
2.4.4	Inhibition of stimulated cytokine production	87
2.4.5	Glucocorticoid sensitivity of cytokine release	89
2.5	Discussion	91

3.	Glucocorticoid sensitivity and vital exhaustion	95
3.1	Abstract	95
3.2	Introduction	96
3.3	Materials and Methods	99
3.3.1	Setting and participants	99
3.3.2	Experimental protocol	99
3.3.3	Assessment of vital exhaustion	100
3.3.4	Glucocorticoid sensitivity and assay	101
3.3.5	Biochemical analyses	102
3.3.6	Statistical analyses	103
3.4	Results	104
3.4.1	Study population and baseline characteristics	104
3.4.2	Stimulation of cytokine production	105
3.4.3	Inhibition of stimulated cytokine production	105
3.4.4	Glucocorticoid sensitivity of cytokine release	106
3.5	Discussion	107
4.	General discussion	112
4.1	Summary of the experimental studies	112
4.2	Discussion of the research approach	114
4.3	Clinical implications of the findings	118
4.4.	Directions for future research	120
5.	References	123